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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.006Despite decades of research, the survival rate of ovarian cancer patients is largely unchanged. Current
chemotherapeutic drugs are effective only transiently because patients with advanced disease even-
tually develop resistance. Thus, there is a pressing need for identifying novel therapeutic targets in
ovarian cancer. Mounting evidence suggests that angiopoietins (Angpts) may play an essential role in
cancer progression; however, the expression proﬁles and biological effects of Angpts on ovarian cancer
remain largely unknown. Here, we show that, compared with their normal counterparts, expressions of
Angpt1, Angpt2, and Angpt4 are increased in ovarian cancer cells and tissues and that human ovarian
cancer cells also express the Angpt receptor Tie-2ereceptor tyrosine kinase. We show that increased
expression of Angpt1, Angpt2, or Angpt4 promotes intraperitoneal growth of ovarian cancers and
shortens survival of the experimental mice. We further show, for the ﬁrst time, that Angpts promote
accumulation of cancer-associated ﬁbroblasts and tumor angiogenesis in the ovarian cancer microen-
vironment, as well as enhance ovarian cancer cell proliferation and invasion in vivo. In addition, we
establish a novel function of Angpts in promoting proliferation and invasion and inducing Tie-2 and
extracellular signal-regulated kinase 1/2 activation in ovarian cancereassociated ﬁbroblasts.
Taken together, these data suggest that the AngpteTie-2 functional axis is an important player in
ovarian cancer progression and an attractive target for ovarian cancer therapy. (Am J Pathol 2014, 184:
2285e2296; http://dx.doi.org/10.1016/j.ajpath.2014.05.006)Supported by National Heart, Lung, and Blood Institute grant
RO1HL074117, National Cancer Institute grant R01CA150355 (Q.Y.), and
National Cancer Institute institutional training grant 5T32CA078207-12
(M.K.B.).
Disclosures: None declared.Ovarian cancer is the most lethal gynecologic malignancy.1
Current chemotherapies for ovarian cancer patients are effec-
tive only transiently because patients with advanced disease
eventually develop resistance despite signiﬁcant initial re-
sponses.2,3 Extensive studies have shown a critical role for
angiogenesis in the progression of ovarian cancer, and targeted
antievascular endothelial growth factor (VEGF) and VEGF
receptor (VEGFR) therapies have shown a clinical beneﬁt for
ovarian cancer patients.4e7 However, these effects often were
transient and followed by therapeutic resistance.5,6 One of the
potential mechanisms underlying the observed resistance is
activation of alternative angiogenic signaling pathways thatstigative Pathology.
.bypass these inhibitors.8e10 Thus, simultaneously targeting
multiple angiogenic signaling pathways likely will achieve
better clinical outcomes for cancer patients.
In addition to the VEGFeVEGFR signaling pathway,
the Tie-2ereceptor tyrosine kinase (RTK), and their li-
gands, angiopoietin (Angpt)1, Angpt2, and Angpt4, are
Brunckhorst et alattractive targets for cancer therapy.11 Altered expression
proﬁles of angiopoietins have been detected in several
cancer types and studies have shown the essential roles of
angiopoietins in angiogenesis and progression of certain
cancer types.11e13 However, the expression proﬁles and
biological effects of angiopoietins on ovarian cancer
remain largely unknown. Therapeutic agents targeting this
functional axis are currently in different stages of pre-
clinical and clinical development. Most of the agents in
development selectively target Angpt2, and the remaining
few target Angpt1 and Tie-2 with more broad speciﬁcity.
Little has been done to investigate the comparative effects
of Angpt1, Angpt2, and Angpt4 on cancer progression, and
the mechanisms underlying these effects are not fully un-
derstood. There are still several urgent questions that need
be answered to guide effective targeting of the Angpte
Tie-2 functional axis. For example, it remains to be
determined whether merely targeting Angpt2 is enough to
block the procancer progression effect of this functional
axis, and it remains to be determined if simultaneously
targeting Angpt2 and Angpt1/Angpt4 will be a more
effective therapeutic strategy that leads to better clinical
outcomes for cancer patients. To provide guidance to the
ongoing drug development efforts that target this func-
tional axis, it is necessary to understand the relative con-
tributions of Angpt1, Angpt2, and Angpt4 to ovarian
cancer progression and the mechanisms underlying their
effects. The studies reported herein answer these questions.
We show that expressions of Angpt1, Angpt2, and
Angpt4 are increased in human serous ovarian cancers,
including primary and secondary cancer lesions, compared
with normal ovary, and that a panel of human ovarian
cancer cells express Angpt1, Angpt2, and Angpt4, as well
as their receptor, Tie-2. We establish for the ﬁrst time that
increased expression of Angpt1, Angpt2, and Angpt4
signiﬁcantly promotes the intraperitoneal growth of
ovarian cancers with comparable efﬁciency and results in
reduced survival of experimental mice. On the contrary,
knockdown of Angpt1 or Angpt4 inhibits the progression
of ovarian cancer in vivo and extends survival of the
experimental mice. Immunohistochemical analyses of
orthotopic tumors show that in addition to a proangiogenic
effect, angiopoietins, especially Angpt2 and Angpt4, pro-
mote accumulation of ovarian cancereassociated ﬁbro-
blasts (OCAFs) within the tumors. We establish for the ﬁrst
time that OCAFs express Tie-2 RTK, and Angpt1, Angpt2,
and Angpt4 promote OCAF proliferation and invasion and
induce activation of Tie-2 and extracellular signal-
regulated kinase (ERK)1/2 in these CAF cells. These re-
sults establish a novel role for angiopoietins in promoting
accumulation and/or expansion of CAFs and suggest a
broad role for angiopoietins in establishing a proeovarian
cancer microenvironment beyond simply promoting tumor
angiogenesis. Furthermore, we show that ovarian cancer
cells also express Tie-2 RTK and that Angpt2 and Angpt4
promote ovarian cancer cell proliferation in vivo and2286enhance invasion of ovarian cancer cells into host organs.
These results suggest that the AngpteTie-2 functional axis
works in a paracrine fashion on endothelial cells and CAFs
to establish a protumor microenvironment as well as in an
autocrine fashion on ovarian cancer cells. Together, these
results suggest that the AngpteTie-2 functional axis is an
important player in ovarian cancer progression and
Angpt1, Angpt2, and Angpt4 are important targets for
ovarian cancer therapy. A therapeutic strategy that targets
Angpt1/Angpt2/Angpt4 or Angpt2/Angpt4 simultaneously
should be developed to safely and more effectively block
this functional axis and to achieve better clinical outcomes
for ovarian cancer patients.
Materials and Methods
Patient Ovarian Cancer Samples, Cells, and Reagents
OVCAR-3ip and SKOV-3ip cells were derived as described.3
Ovarian cancer samples were obtained from the Cooperative
Human Tissue Network at the University of Pennsylvania and
Ohio State University, and details of the human tissues are
provided in the legend to Figure 1. OCAFs were derived from
fresh human ovarian cancer samples from the Cooperative
Human Tissue Network and cultured in ﬁbroblast medium
(FM; ScienCell Research Laboratories, Carlsbad, CA). Human
umbilical vein endothelial cells (HUVECs) were from All-
Cells, LLC (Alameda, CA). Human ovarian surface epithelial
cellswere from theScienCellResearchLaboratories.OVCAR-
3,OVCAR-4,OVCAR-5, OVCAR-8, IGROV1, and SKOV-3
cells were from the National Cancer Institute (Developmental
Therapeutics Program; Division of Cancer Treatment and
Diagnosis Tumor Repository, Bethesda, MD).
Anti-v5 epitope (Life Technologies, Grand Island, NY),
antieTie-2, and anti-Angpt1, anti-Angpt2, and anti-Angpt4
(Santa Cruz, Dallas, TX, and R&D Systems, Minneapolis,
MN), anti-CD31 (Millipore, Billerica, MA, and BD Bio-
sciences, San Jose, CA), antiea-smooth muscle actin
(a-SMA) (Sigma, St. Louis, MO, and R&D Systems), anti-
ERK1/2, antiephospho-ERK1/2 (Santa Cruz Biotechnology
and Cell Signaling Technology, Danvers, MA) antibodies,
and the Premix WST-1 Cell Proliferation Assay System
(Takara Bio, Mountain View, CA) were used in the exper-
iments. Puriﬁed Angpt1, Angpt2, and Angpt4 were obtained
from R&D Systems.
RT-PCR and Expression Constructs
RT-PCR was performed and full-length human Angpt1,
Angpt2, and Angpt4 cDNAs were generated and cloned
along with their COOH-terminal v5-epitope tags to the
retroviral expression vector pQCXIP (BD Biosciences) as
described.12,14,15 All expression constructs were veriﬁed by
DNA sequencing. Retroviruses were generated using these
expression constructs and pVSVG in GP2-293 cells
following the manufacturer’s instructions (BD Biosciences).ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Expression of angiopoietins by ovarian cancers. A: Angiopoietin expression in normal ovary, primary serous ovarian cancer, and serous omental
metastases was assessed by immunohistochemistry using anti-human Angpt1, Angpt2, or Angpt4 antibodies (Santa Cruz Biotechnology). B: Scoring of the
immunohistochemistry results. The intensity of immunoreactivity to anti-Angpt1, Angpt2, and Angpt4 antibody in 12 cases of primary serous ovarian cancer, 12
cases of omental metastases of serous ovarian cancer, and 10 cases of normal ovaries were scored. *P< 0.05. Scale barZ 100 mm. Ab, antibody; Met, metastases.
Angpts Promote Ovarian Cancer GrowthRetrovirus Transduction and Real-Time Quantitative
PCR
OVCAR-3ip and SKOV-3ip cells were transduced with the
retroviruses carrying the empty retroviral expression vector,
the Angpt1-, Angpt2-, or Angpt4-infected cells were
selected for their resistance to puromycin and pooled pop-
ulations of puromycin-resistant cells transduced with empty
expression vector or expressing Angpt1, Angpt2, or Angpt4
were used in the experiments. Anti-v5 monoclonal antibody
(Life Technologies) was used to detect expression of
exogenous v5-tagged Angpt1, Angpt2, and Angpt4.
Quantitative real-time PCR (qPCR) was performed as
described12,16 by using SYBR Green PCR Master Mix
(Roche Diagnostics, Indianapolis, IN) and the Mx3005P
Real-Time PCR Machine (Agilent Technologies, Santa
Clara, CA). The cycling parameters used were 95C for 10
minutes followed by 45 cycles of 95C (15 seconds), 60C
(30 seconds), and 72C (15 seconds), and a melting curve
analysis. Relative quantiﬁcation of the targets was normal-
ized with an endogenous housekeeping gene (glyceralde-
hyde-3-phosphate dehydrogenase) and data analyses were
performed using a comparative (DDCt) method according to
the manufacturer’s instructions (Agilent Technologies).
Western Blot Analysis and ERK Phosphorylation
Serum-free cell culture supernatants were collected from
cultured ovarian surface epithelial cells and ovarian cancer
cells after 48 hours. Serum-free supernatant (2 mL) was
concentrated by NanoSep Centricon-3K (Pall Corporation,
Port Washington, NY) to 100 mL. Cells were extracted
with 4  SDS Laemmli sample buffer without the dye.
Protein concentrations from all of the samples were
determined using Dc Protein Assay Reagents (Bio-Rad,
Hercules, CA). Equal amounts of proteins were analyzed
by Western blot as described.17 Ponceau S staining was
used as a control for loading and transfer efﬁciency forThe American Journal of Pathology - ajp.amjpathol.orgsecreted proteins in cell culture supernatants. Ten percent
b-mercaptoethanol was added to samples as indicated to
reduce disulﬁde bonds.
OCAF cells and HUVECs were cultured until subconﬂuence
and switched to serum-free medium for 24 hours. Puriﬁed
Angpt1, Angpt2, and Angpt4 (R&D Systems), or basic ﬁbro-
blast growth factor/VEGF (as positive controls), were applied to
the serum-starved CAF cells and HUVECs for different lengths
of time. The cells then were lysed and equal amounts of
extracted proteins were analyzed by Western blot using antie
phospho-ERK1/2 and anti-ERK1/2 to detect phosphorylated
and total amounts of ERK1/2 proteins, respectively.
Cell Proliferation and Invasion Assays
Cell proliferation assays were performed by seeding CAFs
or ovarian cancer cells at 2  103 cells/well in 96-well plates
in triplicate in FM medium or 10% fetal bovine serum
RPMI-1640. After 24 hours, the cells were switched to fresh
1:1 mixture of FM:Dulbecco’s modiﬁed Eagle’s medium or
2% fetal bovine serum RPMI 1640 medium in the absence
or presence of 250 ng/mL of angiopoietins. Cell prolifera-
tion assays were performed using the Premix WST-1 Cell
Proliferation Assay System, following the manufacturer’s
instructions.
Invasion assays (Transwell; Corning, Corning Inc., NY)
were performed as described.17 Brieﬂy, 0.5  106 of ovarian
cancer cells or 1  106 of OCAFs in 2% fetal bovine serum
RPMI 1640 medium or a 1:1 mixture of FM:Dulbecco’s
modiﬁed Eagle’s media, respectively, were placed in the
upper chambers of the Matrigel-coated (BD Biosciences)
Transwell inserts (Corning) in triplicate. Two percent fetal
bovine serum RPMI 1640 medium or a 1:1 mixture of
FM:Dulbecco’s modiﬁed Eagle’s media in the presence or
absence of 250 ng/mL of Angpt1, Angpt2, or Angpt4 was
added to the bottom chambers. After incubation at 37C for 30
hours, the ovarian cancer cells and OCAFs that migrated
through the Transwell and reached the underside of the inserts2287
Figure 2 Expression of angiopoietins and Tie-2 protein by ovarian
cancer cells. A: Western blot shows the levels of endogenous Angpt1,
Angpt2, and Angpt4 secreted by HOSEs and a panel of human ovarian cancer
cells. The intensities of approximately 50-kDa Ponceau staining bands on the
transferred membranes were used as the control for protein loading and
transferring efﬁciency. B:Western blot shows the levels of endogenous Tie-2
RTK. Western blot analysis was performed using whole-cell lysates derived
from a panel of human ovarian cancer cells. Total protein (50 mg) was loaded
in each lane. Actin was used as a loading control.
Figure 3 Angiopoietins promote in vivo growth of ovarian cancer cells
and signiﬁcantly shorten the survival length of experimental mice. A:
Establishment of SKOV-3ip and OVCAR-3ip cells expressing v5 epito-
peetagged Angpt1, Angpt2, and Angpt4 or transduced with the empty
expression vector alone (control). Secreted v5-tagged angiopoietins were
detected by anti-v5 monoclonal antibody under nonreducing and reducing
conditions. The multiple banding patterns are consistent with multi-
merization of angiopoietins; angiopoietin monomers are formed under the
reducing condition. The effects of angiopoietins on intraperitoneal pro-
gression of SKOV-3ip (B) and OVCAR-3ip (C) cells and survival curves of the
experimental mice are shown. At least six mice were used for each type of
transduced ovarian cancer cell. *P < 0.05.
Brunckhorst et alwere ﬁxed and stained using the Diff-Quick Stain Set (Poly-
sciences Inc., Warrington, PA). The stained cells in 20
randomly selected 200 microscopic ﬁelds then were coun-
ted using QCapture Suite Software (Qimaging, Surrey, BC).
Intraperitoneal Ovarian Cancer Growth Experiments
Pooled populations of OVCAR-3ip and SKOV-3ip cells
transduced with empty expression vector or overexpressing
Angpt1, Angpt2, or Angpt4 were used for intraperitoneal
tumor growth experiments. Brieﬂy, 2  106 cells were
injected intraperitoneally into each immunocompromised
Rag-2/II2rg mouse (Rag2; Taconic, Hudson, NY). For each
type of infected ovarian cancer cell, 6 to 10 mice were used.
Following an approved Institutional Animal Care and Use
Committee at the Icahn School of Medicine at Mount Sinai
protocol, after injection of the cancer cells, mice were
monitored closely and a mouse survival analysis was per-
formed. Mice were sacriﬁced when they appeared moribund
or displayed signs of distress, at which time they were
recorded as dead. At the conclusion of the experiments,
tumors and adjunct mouse tissues were removed, ﬁxed, and
sectioned for further histologic and immunologic analyses.
Histology, Immunohistochemistry, and
Immunoﬂuorescence
Histology was performed as described.12 Parafﬁn sections
derived from ovarian cancer patients and the ovarian cancer
and adjacent normal mouse tissues derived from the in
vivo experiments were stained immunohistochemically.2288Immunohistochemical analysis of Ki-67, a proliferation
marker, was performed on the tumor sections derived from
OVCAR-3ip control cells and OVCAR-3ip cells expressing
v5-tagged angiopoietins. Ki-67þ cells were counted in ﬁve
randomly selected 400 microscopic ﬁelds derived from
three different tumors for each condition. The percentage of
Ki-67þ tumor cells was determined by dividing the number of
positive tumor cells by the total number of tumor cells per
microscopic ﬁeld. Parafﬁn sections were derived from 12
cases of primary serous ovarian cancer, 12 cases of omental
metastases of serous ovarian cancer, and 10 cases of normal
ovaries, and reacted with anti-Angpt1, anti-Angpt2, or anti-
Angpt4 antibody (Santa Cruz Biotechnology). The immu-
noreactive intensity of each case was scored by two people
independently as follows: 0 indicates negative; 1, weak; 2,
intermediate; and 3, strong staining.12 The scores were aver-
aged, and standard deviations and P values were calculated.
The frozen sections of the ovarian cancer tissues derived
from the in vivo experiments were stained with the ﬂuores-
cein isothiocyanateeconjugated anti-v5 monoclonal antibody
(Life Technologies) and/or the Cy3-conjugated antiea-SMA
antibody (Sigma). The single- and double-stained immuno-
ﬂuorescent images were taken and compared.
Statistical Analysis
Other than survival experiments, the Student’s t-test was used
to analyze statistical differences between the control and
experimental groups. For mouse survival experiments, log-
rank statistical analysis (SigmaPlot version 11.0; Systatajp.amjpathol.org - The American Journal of Pathology
Angpts Promote Ovarian Cancer GrowthSoftware Inc., San Jose, CA) was performed. Differences
were considered statistically signiﬁcant at P < 0.05.
Results
Human Ovarian Cancer Tissues and Cells Express
Endogenous Angiopoietins
Expression of angiopoietins has been reported in a variety of
nonevasculature-associated cell types, including mono-
cytes18 and myocytes,19 and a variety of tumor cells12,20e22;
however, the expression proﬁles of angiopoietins in ovarian
cancer are largely unknown. We therefore performed
immunohistochemical analyses of the sections derived from
12 cases of primary serous carcinoma, 12 cases of omental
metastases of serous carcinoma, and 10 cases of normal
human ovaries. Compared with normal ovary, expression of
Angpt1, Angpt2, and Angpt4 was elevated in primary se-
rous carcinoma as well as in omental metastatic lesions of
serous carcinoma, one of the most common sites of ovarian
cancer metastasis (Figure 1).23 Interestingly, there are
distinct localization patterns of angiopoietins within theFigure 4 Angpt2 and Angpt4 promote ovarian cancer cell proliferation and inv
transduced OVAR-3ip cells reacted with antieKi-67 antibody. A: Representative
OVCAR-3ipAngpt1, OVCAR-3ipAngpt2, and OVCAR-3ipAngpt4 cells. B: Quantiﬁcati
randomly selected 400 microscopic ﬁelds derived from three different tumors fo
dividing the number of Ki-67þ tumor cells by the total number of tumor cells per m
cells. Representative images of H&E-stained intraperitoneal tumor sections deriv
expressing angiopoietins. A and C: Arrows respectively indicate stroma and invade
40 mm (B). T, tumor cells; P, peritoneal tissues.
The American Journal of Pathology - ajp.amjpathol.orgtumor: Angpt1 and Angpt2 are more concentrated in the
tumor cells whereas Angpt4 has a higher expression level in
the tumor stroma (Figure 1A). This pattern is consistent in
both primary and metastatic lesions.
To compare the levels of angiopoietins and Tie-2 tran-
scripts in human ovarian cancer cells and human ovarian
surface epithelial cells (HOSEs) (ScienCell Res Lab), we
performed real-time RT-qPCR analyses and observed higher
expression levels of Angpt1, Angpt2, Angpt4, and Tie2 in
OVCAR-3ip and SKOV-3ip human ovarian cancer cells
compared with normal HOSEs (Supplemental Figure S1).
RT-qPCR results show only the relative transcript levels in
ovarian cancer cells and HOSEs. To conﬁrm that ovarian
cancer cells produce higher levels of endogenous angio-
poietin proteins, we collected and concentrated serum-free
cell culture supernatants derived from a variety of ovarian
cancer cell lines and HOSEs and observed higher levels of
secreted Angpt1, Angpt2, and Angpt4 in ovarian cancer cells
(Figure 2A). Although earlier studies indicated that Tie-2 is
expressed largely by endothelial cells and bone marrow
progenitor cells,24,25 consistent with other ﬁndings,12 our
RT-qPCR results showed that cancer cells express Tie-2asion in vivo. The tumor sections of intraperitoneal tumors derived from the
images of Ki-67estained tumor sections derived from OVCAR-3ipControl,
on of Ki-67þ cells per microscopic ﬁeld. Ki-67þ cells were counted in ﬁve
r each condition. The percentage of Ki-67þ tumor cells was determined by
icroscopic ﬁeld. C: Angpt2 and Angpt4 promote invasion of ovarian cancer
ed from OVCAR-3ip cells transduced with empty expression vector or over-
d ovarian cancer cells in the liver tissues. *P < 0.05. Scale bars: 50 mm (A);
2289
Brunckhorst et altranscripts, as well (Supplemental Figure S1). To establish
that Tie-2 protein is expressed by human ovarian cancer cells,
we performed Western blot analysis using whole-cell lysates
derived from a panel of ovarian cancer cells. We found that
these ovarian cancer cells indeed express endogenous Tie-2
protein (Figure 2B).
Angiopoietins Promote Intraperitoneal Ovarian Cancer
Growth
To establish roles of the angiopoietins in ovarian cancer pro-
gression and compare their relative contributions, we estab-
lished orthotopic mouse models that mimic the development
of intraperitoneal tumors andmetastasis of ovarian cancer cells
to various organs within the abdominal cavity, the condition
associated with the late-stage disease.3 To study the effects of
angiopoietins on ovarian cancer growth and progression, we
expressed exogenous Angpt1, Angpt2, and Angpt4 in SKOV-
3ip and OVCAR-3ip cells. SKOV-3ip and OVCAR-3ip cells
were derived from in vivo selections of their parental cells,
SKOV-3 and OVCAR-3 cells, based on their intraperitoneal
growth ability.3 SKOV-3ip and OVCAR-3ip cells transduced
with the empty expression vector were used as negative con-
trols. The expression of v5-epitopeetagged angiopoietins was
validated byWestern blot analyses of cell culture supernatants
of the transduced ovarian cancer cells (Figure 3A). The mul-
tiple banding patterns of angiopoietins are typical and reﬂect
the multimerization status of the angiopoietins.12,14,15 These
multimers can be dissociated into monomers under reducing
conditions with 10% 2-mercaptoethanol (Figure 3A).
To determine the effects of angiopoietins on ovarian
cancer progression in vivo, the pooled populations of SKOV-
3ip and OVCAR-3ip cells expressing angiopoietins orFigure 5 Angiopoietins promote accumulation of the CAFs in ovarian tum
transduced with empty expression vector or overexpressing angiopoietins were st
tumors. Scale bars: 100 mm (AeH); 50 mm (IeL).
2290transduced with the empty expression vector were injected
intraperitoneally into each immunocompromised Rag-2/
II2rg mouse. Increased expression of Angpt1, Angpt2, and
Angpt4 in OVCAR-3ip and SKOV-3ip cells signiﬁcantly
promoted the cancer progression and reduced the survival
length of experimental mice compared with the controls and
there were no statistically signiﬁcant differences among the
pro-ovarian cancer activities of these angiopoietins in both
ovarian cancer cells (Figure 3, B and C). In SKOV-3ip cells,
Angpt2 showed the most potent promotive effect on intra-
peritoneal growth of the ovarian cancer cells because its
overexpression reduced the median mouse survival to less
than 5 weeks, whereas in OVCAR-3ip cells all three angio-
poietins showed similar pro-ovarian cancer growth activities
(Figure 3, B and C). Taken together, these results suggest that
all three angiopoietins promote the progression of ovarian
cancer in vivo.
To conﬁrm the pro-ovarian cancer activity of angiopoietins,
we knocked down Angpt1 and Angpt4 expression in
OVCAR-3ip and SKOV-3ip cells (Supplemental Figure S2A).
We showed that knockdown of Angpt1 or Angpt4 expression
inhibited the intraperitoneal growth of OVCAR-3ip and
SKOV-3ip cells and signiﬁcantly extended survival of the
experimental mice (Supplemental Figure S2, B and C).
Together, these results established the pro-ovarian cancer
progression effects of angiopoietins and established that
angiopoietins are potential targets for ovarian cancer therapy.
Angiopoietins Promote Ovarian Cancer Cell
Proliferation in Vivo
Given the fact that increased expression of angiopoietins
signiﬁcantly promotes ovarian cancer progression andors. Tumor sections derived from abdominal OVCAR-3ip ovarian cancers
ained with H&E (AeD) and antiea-SMA (EeL), highlighting CAFs in these
ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Angiopoietins promotes OCAF proliferation. A and B: Estab-
lishment and characterization of primary OCAFs. A: Western blot analysis of
whole-cell lysates of ﬁve preparations of primary OCAFs (lanes 3 to 7) and
human dermal skin ﬁbroblasts (lanes 1 to 2) using antiea-SMA antibody.
Actin was used as a loading control. B: Immunocytochemical analyses of a-
SMA expression by OCAFs and human dermal skin ﬁbroblasts. C and D: OCAF
proliferation assays in the presence or absence of 250 ng/mL of Angpt1,
Angpt2, or Angpt4. Two different preparations of OCAFs were used. The
results show representative means  SDs of one of the two independent
experiments performed in triplicate. *P < 0.05. Scale bar Z 20 mm.
hAngpt, human Angpt.
Angpts Promote Ovarian Cancer Growthreduces the survival of experimental mice, we assessed the
biological effects of angiopoietins on ovarian cancer cells by
investigating whether angiopoietins are capable of promot-
ing in vivo proliferation of the ovarian cancer cells. Immu-
nohistochemical analysis of Ki-67, a proliferation marker,
was performed on the tumor sections derived from
OVCAR-3ip control cells and OVCAR-3ip cells with
increased expression of angiopoietins. These data showed
that increased expression of Angpt2 and Angpt4 signiﬁ-
cantly increased the number of Ki-67þ and proliferating
ovarian cancer cells (Figure 4, A and B). The percentage of
Ki-67þ tumor cells was determined by dividing the number
of Ki-67þ tumor cells by the total number of tumor cells per
microscopic ﬁeld.
Angiopoietins Promote Ovarian Cancer Invasion into
Host Tissues
To investigate the effects of angiopoietins on ovarian cancer
invasion, we performed histologic analyses of peritoneal
and liver tissues derived from the tumor-bearing experi-
mental mice. We found that increased expression of Angpt2,
and, to a lesser extent, Angpt4, promotes invasion of the
ovarian cancer cells into host peritoneal (Figure 4C) and
liver tissue parenchyma (Figure 4C). The borders of host
peritoneal tissues in mice with tumors derived from
OVCAR-3ip with increased Angpt2 expression were nearly
indistinguishable from tumor tissues that invaded and
literally mixed with the host tissue (Figure 4C).
Angiopoietins Promote Tumor Angiogenesis and
Accumulation of CAFs in Ovarian Tumors
Protumor angiogenesis effects of angiopoietins have been
well established in other cancer types.11,12,26,27 Immunohis-
tochemical analyses conﬁrmed that Angpt1, Angpt2, and
Angpt4 promote tumor angiogenesis during ovarian cancer
progression (Supplemental Figure S3). We also observed that
the tumor sections derived from the ovarian cancer cells with
increased expression of angiopoietins appeared to have more
inﬁltrating host stroma, recognizable by its distinct swirling
pattern between clusters of epithelial-like ovarian cancer cells
(data not shown). It is well established that tumor stroma
plays important roles in promoting cancer invasion, metas-
tasis, progression, and chemoresistance,28e30 and that the
CAFs are associated with an increased risk of invasion and
metastasis of a variety of tumor types.31e33 To assess the
presence of CAFs in these ovarian cancers, we performed
immunohistochemical analyses on these tumor sections to
detect a-SMA, an intermediate-ﬁlamenteassociated protein
that routinely is used as a marker for CAFs.34,35 Results from
theses analyses showed a striking increase in the amount of
a-SMAepositive CAFs in the ovarian cancers derived
from OVCAR-3ip and SKOV3-ip cells expressing increasing
amounts of angiopoietins compared with their control coun-
terparts (Figure 5 and Supplemental Figure S4), suggesting aThe American Journal of Pathology - ajp.amjpathol.org 2291
Brunckhorst et alnovel role of angiopoietins in regulating CAF inﬁltration and/
or expansion.
To further assess the relative localization of angiopoietin-
expressing ovarian cancer cells and a-SMAepositive CAFs,
and taking advantage of our knowledge that Angpt4 is local-
ized on the surface of ovarian cancer cells (Supplemental
Figure S5), we performed co-immunoﬂuorescence localiza-
tion experiments using the ﬂuorescein isothiocyanatee
conjugated anti-v5 antibody to detect the ovarian cancer cells
expressing v5-tagged Angpt4 and the Cy3-conjugated antie
a-SMAantibody to detect CAFs. Results showed that Angpt4-
positive ovarian cancer cells are inﬁltrated by the a-SMAþ
CAFs (Supplemental Figure S6), suggesting a potential role of
angiopoietins in attracting CAFs to the angiopoietin-
expressing ovarian cancer cells.
Angiopoietins Promote OCAF Proliferation and
Invasion
The observed increase in the amount of CAFs in the ovarian
cancer tissues that express higher levels of angiopoietins
suggests that angiopoietins directly or indirectly (through
other soluble factors) affect cellular behaviors of OCAFs. To
investigate this possibility, we ﬁrst established several prepa-
rations of primary OCAFs from fresh ovarian cancer samples
(The Cooperative Human Tissue Network, University of
Pennsylvania and Ohio State University). We validated theseFigure 7 Angiopoietins promote OCAF invasion through Matrigel. Invasion of
Angpt2, or Angpt4. A: Representative images of the OCAF cells show migration thro
through the Transwell inserts in 20 randomly selected 200 microscopic ﬁelds we
preparations of OCAFs were used in the studies. The results show representative
triplicate. *P < 0.05. Scale bar Z 150 mm.
2292cells by assessing their expressions of the CAF marker a-
SMA. Two preparations of CAFs from two different ovarian
cancer samples that express higher levels of SMA (Figure 6A)
were validated further by immunocytochemistry using the
anti-SMA antibody to establish thatmost, if not all, of the cells
in the preparations are highly SMA positive (Figure 6B).
These CAF cells were used in proliferation assays and the
results showed that Angpt1, Angpt2, and Angpt4 promote
OCAF proliferation (Figure 6, C and D). We then assessed the
effects of angiopoietins on invasion of these OCAFs through
Matrigel in the Transwell invasion assays. Our results showed
that Angpt4, and, to a lesser extent, Angpt2 and Angpt1,
promote OCAF invasion through Matrigel (Figure 7, AeC).
These results suggest that angiopoietins promote inﬁltration
and expansion of OCAFs in ovarian cancers.
To assess whether the pro-ovarian cancer activities of
angiopoietins are exerted through their direct effects on
ovarian cancer and/or their indirect effect on OCAFs, we
performed similar cell proliferation and Matrigel invasion
assays usingOVCAR-3ip and SKOV-3ip cells in the presence
and absence of angiopoietins. Although angiopoietins did not
lead to a statistically signiﬁcant increase of proliferation of
OVCAR-3ip and SKOV-3ip cells in vitro, angiopoietins
signiﬁcantly promoted invasion of these ovarian cancer cells
through Matrigel (Supplemental Figure S7), suggesting that
angiopoietins affect ovarian cancer cells directly and indirectly
through OCAFs.OCAFs was assessed in the presence or absence of 250 ng/mL of Angpt1,
ugh the Matrigel-coated Transwell inserts. B and C: The OCAFs that migrated
re counted and their mean values with SD were quantitated. Two different
means  SDs of one of the two independent experiments performed in
ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Angiopoietins promote activation of Tie-2 RTK and ERK1/2
kinases in OCAFs. A: OCAFs express Tie-2 RTK. Expression of Tie-2 by OCAFs
(lanes 3 to 4) and HUVECs (lanes 1 to 2) was determined by Western blot
using antieTie-2 antibody (Santa Cruz Biotechnology). Fifty microgram of
total protein was loaded in each lane. Actin was used as a loading control.
Serum-starved OCAF cells and HUVECs were supplied with serum-free medium
(SFM) or SFM containing 250 ng/mL of Angpt1, Angpt2, or Angpt4, or 20 ng/
mL of basic ﬁbroblast growth factor (bFGF) (for OCAFs)/VEGF (for HUVECs) for
1 hour (B), 3 hours (C), and 24 hours (C). The cells were lysed and proteins
were analyzed by Western blot with antiephospho-Tie2 (B) and phospho-
ERK1/2 (C), with anti-actin (B) or anti-ERK1/2 (C) antibodies.
Angpts Promote Ovarian Cancer GrowthAngiopoietins Induce Activation of Tie-2 and ERK1/2
in OCAFs
To assess how angiopoietins affect OCAF behavior, we ﬁrst
investigated whether OCAFs express the Tie-2 receptor and
found that OCAFs indeed express Tie-2 RTK, although the
level of Tie-2 in OCAFs is much lower than that in endothelial
cells (Figure 8A). To determine and compare the effects of
angiopoietins on activation of Tie-2 RTK and its downstream
signaling pathway in these OCAFs and HUVECs, we treated
serum-starved CAFs and HUVECs with Angpt1, Angpt2,The American Journal of Pathology - ajp.amjpathol.orgAngpt4, or basic ﬁbroblast growth factor/VEGF for various
lengths of time. Angpt1, Angpt2, and Angpt4 induced Tie2
activation and activation of downstream ERK1/2 kinase in
OCAFs and HUVECs (Figure 8, B and C). Together, these
results establish a novel function for angiopoietins and suggest
that in addition to endothelial cells, Angpts can regulate CAF
function directly and promote their proliferation and invasion.
These data also suggest that angiopoietins affect ovarian
cancer progression through modulating the tumor microen-
vironment as well as affecting tumor cells through Tie-2 RTK.
Discussion
Angiopoietins Play Key Roles in Ovarian Cancer
Progression and Are Attractive Therapeutic Targets for
Ovarian Cancer
Tumor angiogenesis is regulated by proangiogenic and
antiangiogenic factors produced by tumor cells and the
tumor-associated host cells.36,37 Sufﬁcient angiogenesis is
essential for ovarian cancer growth and progression. Antie
angiogenesis-based therapies such as anti-VEGF/VEGFR
therapies have shown clinical beneﬁt for ovarian cancer pa-
tients; however, resistance to anti-VEGF and -VEGFR thera-
pies often occurs.4e7 One of the potential mechanisms of the
resistance is activation of alternative angiogenic signaling
pathways, which lead to demands of better understanding of
other key angiogenic factors such as angiopoietins.
The expression proﬁles of angiopoietins in various cancer
types have been established; however, their expression, effects,
and the mechanisms underlying their effects on ovarian cancer
previously were unknown. Here, we show for the ﬁrst time the
angiopoietin expression pattern/proﬁles in human ovarian can-
cer tissues/cells and establish that Angpt1, Angpt2, and Angpt4
promote ovarian cancer growth and progression. Our results
show that Angpt2 and Angpt4 promote proliferation and inva-
sion of ovarian cancer cells and that in addition to promoting
tumor angiogenesis, angiopoietins stimulate accumulation of
CAFs in ovarian cancers. Furthermore, we show that angio-
poietins promote proliferation and invasion of OCAFs and that
angiopoietins induce activationofTie-2 andERK1/2 inOCAFs,
which likely mediates the effects of angiopoietins on OCAFs.
Together, our results establish that all three angiopoietins play
important roles in promoting ovarian cancer progression and
the angiopoietineTie-2 functional axis provides a promotive
signal to cancer cells in addition to their positive effects on the
tumor microenvironment (CAFs and endothelial cells). Our
results further suggest that the angiopoietin/Tie2 functional axis
is an ideal target for ovarian cancer therapy because it affects
cancer cells and their microenvironment simultaneously.
A Novel Promotive Role of Angiopoietins in Regulating
CAFs
It has beenwell established thatCAFshavewide-ranging effects
on various aspects of the tumor phenotype, including promotion2293
Brunckhorst et alof proliferation, invasion, and angiogenesis.29,30,33,38e41 Our
data indicated that angiopoietins, especially Angpt2 and
Angpt4, promote accumulation of CAFs in ovarian cancer. The
results are consistent with the previous reports that another
angiogenic factor, VEGF, can induce reactive stroma.42 A study
has shown that conditioned medium from SKOV-3 ovarian
cancer cells is capable of inducing the transdifferentiation of
normal ovarian ﬁbroblasts to a reactive population positive for
a-SMA,41 although the factor(s) that mediate(s) this effect was
not identiﬁed.Thedata presentedhere suggest that angiopoietins
play important roles in promoting inﬁltration and/or prolifera-
tion of CAFs. Angiopoietins modestly promote in vitro prolif-
eration of OCAFs and enhance OCAF invasion through
Matrigel, suggesting that angiopoietins promote CAF inﬁltra-
tion as well as expansion. Further studies are required to
distinguish the effects of angiopoietins deﬁnitively on recruit-
ment and expansion of CAFs in vivo. We showed that OCAFs
express Tie-2 RTK and that angiopoietins induce activation of
Tie-2 and a Tie-2 downstream signaling component, ERK1/2,
suggesting that angiopoietins affectOCAFs throughTie-2RTK.
It has been established that CAFs can secrete proteases to
degrade the extracellular matrix, literally paving the way for
cancer cell migration and invasion.43 Once localizedwithin the
tumor, these OCAFs can promote invasive and angiogenic
phenotypes. In addition to promoting tumor angiogenesis,
angiopoietins may enhance ovarian tumor progression by
simulating CAF accumulation, which in turn promotes inva-
sion, metastasis, and progression of the cancer cells. Thus,
blockage of the angiopoietin-induced CAF accumulation may
be an effective therapeutic strategy to combat ovarian cancer.
Expression of Tie-2 by a Variety of Different Cell Types
Suggests Wider Roles of the AngpteTie-2 Functional
Axis
Although Tie-2 expression originally was discovered in
endothelial cells and hematopoietic stem cells, recent studies
have shown Tie-2 expression in a variety of cell lineages,
including monocytes,18 megakaryocytic cells,44 and cancer
cells.12,21,45 Similarly, our studies showed that ovarian cancer
cells express Tie-2. These data are consistent with previous
reports indicating that tumor cells exploit vascular proteins in a
cell-autonomous manner because Lichtenberger et al46 re-
ported that autocrine VEGF signaling is required for epithelial
tumor cell proliferation. We previously showed that glioblas-
toma multiforme cells express Tie2 and angiopoietins, which
in turn can induce signaling in a cell-autonomous manner,12
and here we show that angiopoietins promote ovarian cancer
invasion in vitro (Supplemental Figure S7), supporting a direct
role of angiopoietins in ovarian cancer cells.
In addition to signaling through their receptor Tie-2,
angiopoietins also are known to function through integrins.
Angpt1 was found to induce PC12 neurite outgrowth in a
Tie2-independent and b1-integrinedependent manner,47 and
to reduce cardiac hypertrophy through integrin, but not Tie-
2.48 Furthermore, Angpt2 stimulates breast cancer metastasis2294through the a5b1 integrin-mediated, but not Tie-2emediated,
signaling pathway.49 Additional detailed studies are required
to determine whether integrins are involved in mediating the
effects of angiopoietins on OCAFs and ovarian cancer cells.
Targeting Angpt2 and Angpt4 Simultaneously Is a New
Cancer Therapy Strategy
Because of the potential important roles of Angpt1 in the
maintenance of normal vasculature and the limited knowledge
of Angpt4, the efforts of targeting angiopoietins have been
focused on Angpt2.11,50 Unlike Angpt1, Angpt4 has limited
expression in normal tissues.51 We recently established that
Angpt4 is up-regulated in human glioblastomamultiforme and
plays a key role in glioma growth and progression.12 Our
current study showed that in addition to Angpt1 and Angpt2,
Angpt4 is highly expressed by human ovarian cancer and
promotes ovarian cancer growth and progression. Our results
suggest that simply blocking Angpt2 function/bioactivity may
not be sufﬁcient to interfere with the AngpteTie-2 functional
axis in ovarian cancer/glioblastoma multiforme and other
cancer types in which Angpt4 plays an essential protumor role.
Safely and more effectively blocking protumor activity of the
AngpteTie-2 functional axis likely requires simultaneously
targeting Angpt2 and Angpt4 in human cancers.Acknowledgment
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